Thus, CCL22, through its interaction with its receptor CCR4, establishes the local microenvironment to regulate adipose beiging and energy homeostasis, offering therapeutic potential for preventing obesity and related metabolic disorders. This evidence concerns the gene CCR4 and Other metabolic disease.